Aska Report

Overview

The report describes ASKA Pharmaceutical's FY2016 launch of Rifxima and Luteum, expansion of Candesartan generics, and three business alliances. It presents ASKA PLAN 2020's consolidated targets of ¥70 billion in net sales, a 10% operating profit margin and 8% ROE. Consolidated FY2016 net sales were ¥48,527 million.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2016
Period: 1 April 2016 – 31 March 2017
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services